English High Court denies Mylan a stay in Neurim litigation

Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

Big Pharma

Mylan gets green light to challenge Neurim melatonin patent

25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Americas

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.